| Literature DB >> 33709243 |
Feiyu Shi1,2,3, Gaixia Liu1,2,3, Qi Sun1,2,3, Haowei Zhang1,2,3, Hongtao Wu2,3, Xiaobin Xue1,2, Yingchao Li4, Junjun She5,6,7.
Abstract
Third space robotic and endoscopic cooperative surgery (TS-RECS) is a novel minimally invasive surgery for resecting gastric submucosal tumours (GSMTs), which could accomplish the completely oncological curability and maximal functional preservation. This study investigated the clinical outcomes and gastrointestinal function after TS-RECS versus laparoscopic wedge resection (LWR) for GSMTs. This was a single-centre retrospective study that included 130 patients with GSMTs who underwent LWR or TS-RECS from 2013 to 2019. To overcome selection biases, we performed propensity score matching (1:1) using seven covariates that could impact the group assignment and outcomes. Then, the clinical outcomes and gastrointestinal function in the LWR and TS-RECS groups were compared in a matched cohort. Among the 130 enrolled patients, 96 patients underwent LWR, and 34 underwent TS-RECS and were matched into 30 patients for each group. There was no significant difference in the operation time between the two groups (P = 0.543). However, the TS-RECS group had significantly less blood loss (20,5-100 vs 95,10-310 ml, P < 0.0001) and better postoperative recovery in terms of time to oral intake (2,2-4 vs 3,2-6 days, P < 0.0001) and postoperative hospital stay (5,4-10 vs 8.5,5-16 days, P < 0.0001) than the LWR group. The severity and frequency scores of postoperative gastrointestinal symptoms in the TS-RECS group were significantly lower than those in the LWR group. The median follow-up period was 24 months (10-60 months) in the LWR group and 18 months (10-27 months) in the TS-RECS group, and there was in total a single recurrence in the LWR group. TS-RECS appears to be a technically safe and effective surgery with preservation of gastrointestinal function for resection of GSMT resection.Entities:
Keywords: Clinical outcomes; Gastrointestinal function; Gastrointestinal submucosal tumours; Laparoscopic wedge resection; Third space robotic and endoscopic cooperative surgery
Mesh:
Year: 2021 PMID: 33709243 PMCID: PMC8995283 DOI: 10.1007/s13304-021-01014-6
Source DB: PubMed Journal: Updates Surg ISSN: 2038-131X
Fig. 1Flowchart of patient screening and grouping. SMTs, submucosal tumours; LWR, laparoscopic wedge resection; TS-RECS, third space robotic and endoscopic cooperative surgery
Baseline clinicopathologic characteristics of LWR group and TS-RECS group before and after PSM
| Categories | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
| LWR group (n=96) | TS-RECS (n=34) | LWR group (n=30) | TS-RECS (n=30) | |||
| Age, years | 63.06±9.24 | 56.88±11.44 | 0.002 | 57.43±10.53 | 57.73±11.47 | 0.916 |
| Gender, n | ||||||
| Male | 54 | 20 | 0.842 | 20 | 19 | 0.787 |
| Female | 42 | 14 | 10 | 11 | ||
| BMI, kg/m2 | 22.96±2.70 | 22.04±1.87 | 0.069 | 22.79±2.57 | 22.05±1.93 | 0.216 |
| ASA score, n | ||||||
| I | 57 | 20 | 0.918 | 18 | 17 | 0.834 |
| II | 35 | 12 | 11 | 11 | ||
| III | 4 | 2 | 1 | 2 | ||
| Clinical symptoms, n | ||||||
| No | 76 | 24 | 0.308 | 26 | 25 | 0.718 |
| Yes | 20 | 10 | 4 | 5 | ||
| Previous abdominal surgery, n | ||||||
| No | 87 | 31 | 0.924 | 28 | 26 | 0.389 |
| Yes | 9 | 3 | 2 | 4 | ||
| Tumour size, mm | 40 (14 - 90) | 35 (15 - 65) | 0.039 | 34 (15 - 90) | 35 (15 - 60) | 0.716 |
| Tumour location, n | ||||||
| Cardia | 0 | 2 | 0.016 | 0 | 0 | 0.212 |
| Upper-third | 56 | 16 | 17 | 16 | ||
| Middle-third | 28 | 11 | 6 | 11 | ||
| Low-third | 12 | 3 | 7 | 3 | ||
| Pyloric | 0 | 2 | 0 | 0 | ||
| Pathological diagnosis, n | ||||||
| GIST | 83 | 30 | 0.792 | 25 | 26 | 0.718 |
| No GISTa | 13 | 4 | 5 | 4 | ||
| Mitotic indexb (per 50 HPF), n | ||||||
| ≤5 | 72 | 27 | 0.573 | 23 | 24 | 0.513 |
| 6-10 | 8 | 3 | 1 | 2 | ||
| >10 | 3 | 0 | 1 | 0 | ||
| Fletcher risk classificationb, n | ||||||
| Very low risk | 8 | 1 | 0.206 | 4 | 1 | 0.203 |
| Low risk | 50 | 24 | 16 | 21 | ||
| Intermediate risk | 21 | 5 | 3 | 4 | ||
| High risk | 4 | 0 | 2 | 0 | ||
| C-kit mutational status (CD117)b, n | ||||||
| Positive | 78 | 28 | 0.900 | 24 | 25 | 1.000 |
| Negative | 5 | 2 | 1 | 1 | ||
| Ki-67 labelling indexb, n | ||||||
| <10% | 66 | 28 | 0.083 | 21 | 24 | 0.627 |
| ≥10% | 17 | 2 | 4 | 2 | ||
BMI, body mass index; ASA, American Society of Anesthesiologists; GIST, gastrointestinal stromal tumors; LWR, laparoscopic wedge resection; TS-RECS, the third space robotic and endoscopic cooperative surgery; PSM, propensity score matching
aNo GIST included 2 lipomas, 5 schwannomas, 6 leiomyomas in LWR group, and 2 schwannomas and 2 leiomyomas in TS-RECS group
bOnly for GIST
Comparison of clinical outcomes between LWR group and TS-RECS group after propensity score matching
| Categories | LWR group ( | TS-RECS ( | |
|---|---|---|---|
| Operative time, min | 112.5 (70–280) | 115.0 (75–235) | 0.543 |
| Intraoperative blood loss, ml | 95.0 (10–310) | 20.0 (5–100) | 0.000 |
| Conversion, n | 0 | 0 | 1.000 |
| En bloc resection, n | 30 | 30 | 1.000 |
| Resection margin, n | |||
| R0 | 30 | 30 | 1.000 |
| R1 | 0 | 0 | |
| Time to oral intake, days | 3 (2–6) | 2 (2–4) | 0.000 |
| Postoperative hospital stays, days | 8.5 (5–16) | 5.0 (4–10) | 0.000 |
| Complications, n | 5 | 2 | 0.228 |
| Pneumonia | 0 | 1 | |
| Abdominal incision infection | 0 | 1 | |
| Anastomotic bleeding | 1 | 0 | |
| Gastric emptying disorder | 2 | 0 | |
| Leakage | 2 | 0 | |
| Follow-up time, months | 24 (10–60) | 18 (10–27) | 0.004 |
| Recurrence, n | 1 | 0 | 0.313 |
| Recurrence-related death, n | 0 | 0 | 1.000 |
LWR laparoscopic wedge resection, TS-RECS third space robotic and endoscopic cooperative surgery
Fig. 2The frequency of 15 gastrointestinal symptoms as evaluated with the Gastrointestinal Symptom Rating Scale (GSRS) in the LWR and TS-RECS groups. a Frequency of 15 gastrointestinal symptoms in the LWR group (blue) and TS-RECS group (red) three months postoperatively. b Frequency of 15 gastrointestinal symptoms in the LWR group (blue) and TS-RECS group (red) 6 months postoperatively
Fig. 3The score of 15 gastrointestinal symptoms as evaluated with the Gastrointestinal Symptom Rating Scale (GSRS) in the LWR and TS-RECS groups. a The mean score of 15 gastrointestinal symptoms in the LWR group and TS-RECS group 3 months and 6 months postoperatively. b Total mean GSRS scores of the LWR group and TS-TECS group 3 months and 6 months postoperatively. c GSRS scores of five symptom clusters in the LWR and TS-RECS groups 3 months postoperatively. d Five symptom cluster GSRS scores of the LWR and TS-RECS groups 6 months postoperatively. POD, postoperative day; ***, P < 0.0001; **, P < 0.001; *, P < 0.05
The score of Gastrointestinal Symptom Rating Scale at 3 and 6 months after surgery in LWR group and TS-RECS group
| LWR | TS-RECS | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Mean | 95% CI | Mean | 95% CI | ||||||
| GSRS total | POD 3 months | 5.97 | 5.14 | 6.79 | 4.33 | 3.67 | 5.00 | 0.003 | |
| POD 6 months | 3.50 | 2.86 | 4.14 | 2.33 | 1.68 | 2.99 | 0.012 | ||
| Abdominal pain syndrome | POD 3 months | 1.67 | 1.22 | 2.11 | 1.37 | 0.92 | 1.81 | 0.331 | |
| POD 6 months | 0.40 | 1.19 | 0.61 | 0.27 | 0.07 | 0.46 | 0.345 | ||
| Indigestion syndrome | POD 3 months | 2.23 | 1.79 | 2.68 | 1.10 | 0.74 | 1.46 | 0.000 | |
| POD 6 months | 1.23 | 0.96 | 1.51 | 0.77 | 0.48 | 1.06 | 0.019 | ||
| Reflux syndrome | POD 3 months | 1.67 | 1.15 | 2.18 | 1.63 | 1.07 | 2.20 | 0.929 | |
| POD 6 months | 1.03 | 0.62 | 1.44 | 0.87 | 0.5 | 1.23 | 0.536 | ||
| Constipation syndrome | POD 3 months | 0.23 | -0.06 | 0.52 | 0.23 | 0.00 | 0.47 | 1.000 | |
| POD 6 months | 0.50 | 0.16 | 0.84 | 0.23 | 0.07 | 0.39 | 0.151 | ||
| Diarrhoea syndrome | POD 3 months | 0.27 | 0.07 | 0.46 | 0.20 | -0.01 | 0.41 | 0.632 | |
| POD 6 months | 0.33 | 0.05 | 0.62 | 0.13 | 0.00 | 0.26 | 0.196 | ||
POD postoperative day, GSRS Gastrointestinal Symptom Rating Scale, LWR laparoscopic wedge resection, TS-RECS third space robotic and endoscopic cooperative surgery